Pexmetinib (ARRY-614): Dual Inhibitor for Cytokine Suppre...

2026-01-19

Pexmetinib (ARRY-614) stands out as a rigorously validated dual inhibitor of p38 MAPK and Tie2 receptor tyrosine kinase, enabling targeted cytokine synthesis suppression in myelodysplastic syndromes and inflammatory models. This guide translates recent structural and workflow insights into practical protocols, troubleshooting strategies, and advanced applications, ensuring sensitive, reproducible results for bench researchers.